


Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. PLOVIN-3 A		SERIAL NO. 7,64,149	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Eberhard NIESCHLAG et al.			
				FILING DATE JANUARY 19, 2001		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RB	AA	5,035,891	30JUL91	RUNKEL et al.			
	AB	5,965,552	12OCT99	BERLINER et al.			
	AC	5,855,905	05JAN99	OETTEL et al.			
	AD	4,210,644	01JUL80	EWING et al.			
	AE	5,633,242	27MAY97	OETTEL et al.			
	AF	5,583,129	10DEC96	SPONA et al.			
	AG	4,018,919	19APR77	BLACK			
	AH	5,811,117	22SEP98	HASHIMOTO et al.			
	AI	RE 36,247	06JUL99	PLUNKETT et al.			
RB	AJ	5,711,962	27JAN98	CORDES et al.			
	AK						
	AL						
	AM						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
RB	AO	0 773 028 A1	14MAY97	EP			
	AP	0 696 454 A2	14FEB96	EP			
	AQ	0 587 047 A2	16MAR94	EP			
	AR						
	AS						
	AT						
	AU						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
RB	AW	E. NIESCHLAG et al., "Testosterone Therapy," <i>Male Reproductive Health and Dysfunction</i> , pp. 297-309 (1997)					
	AX	Beatriz Couzin et al., "The Antigonadotropic Activity of Progestins (19-Nortestosterone and 19-Norprogesterone Derivatives) Is not Mediated through the Androgen Receptor," <i>Journal of Clinical Endocrinology and Metabolism</i> , 81, No. 12, pp. 4218-4223 (1996)					
	AY	M.A. Okon et al., "A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of "period free" hormone replacement therapy," <i>Human Reproduction</i> , 31, No. 8, pp. 2261-2265 (1998)					
RB	AZ	J.F. Guerin et al., "Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens," <i>International Journal of Andrology</i> , 11, pp. 187-199 (1988)					
Examiner Rachel M. Bennett					Date Considered 12/19/07		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. PLOVIN-3	SERIAL NO. 09/764,149
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Eberhard NIESCHLAG et al.	
				FILING DATE JANUARY 19, 2001	GROUP
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)					
RB	AAA	M.C. Merrigiola et al., "Low Dose of cyproterone acetate and testosterone enanthate for contraception in men," <i>Human Reproduction</i> , 13, pp. 1225-1229 (1998)			
	AAB	Eds. Nieschlag E. Behre HM, "Experimental Approaches," <i>Hormone Male Contraception Andrology - Male Reproductive Health and Dysfunction</i> , pp. 388-393 (1997)			
	AAC	F. Neuman et al., "Androgens II and Anti-Androgens," <i>Springer-Verlag, Berlin, Heidelberg</i> , pp. 436-437 (1974)			
	AAD	Fuhrmann et al., "Stable transfection of androgen receptor and MMTV-CAT into mammalian cells: inhibition of cat expression by anti-androgens," <i>J. Steroid Biochem. Mol. Biol.</i> , 42(8), p. 787 (1992)			
	AAE	K.H. Fritzemeier et al., "In Vitro and In Vivo Models to Characterize Estrogens and Antiestrogens," <i>Handbook of Experimental Pharmacology</i> , Vol. 135, pp. 6-43 (1999)			
	AAF	E. Nieschlag et al., "Testosterone in male contraception," <i>Testosterone: action, deficiency, substitution</i> , pp. 513-528 (1998)			
	AAG	H.M. Behre et al., "Potential of Testosterone Buciclate for Male Contraception: Endocrine Differences between Responders and Nonresponders," <i>Journal of Clinical Endocrinology and Metabolism</i> , 80, No. 8, pp. 2394-2403 (1995)			
	AAH	M.C. Merrigiola et al., "A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive," <i>Journal of Clinical Endocrinology and Metabolism</i> , 81, pp. 3018-3023 (1996)			
	AAI	R.A. Bebb, "Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach," <i>Journal of Clinical Endocrinology and Metabolism</i> , 81, pp. 757-762 (1996)			
	AAJ	C.J. Bagatell et al., "Comparison of a Gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens," <i>Journal of Clinical Endocrinology and Metabolism</i> , 77, No. 2, pp. 427-432 (1997)			
	AAK	M.C. Merrigiola et al., "An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men," <i>Fertility and Sterility</i> , 68, pp. 84-850 (1997)			
RB	AAL	World Health Organization, "Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men," <i>Fertility and Sterility</i> , 65, pp. 84-850 (1997)			
	AAM	E. Nieschlag et al., "Aufgaben und Ziele der Andrologie - Grundlagen und Klinik der reproduktiven Gesundheit des Mannes," pp. 8-9 (1996)			
RB	AAN	D. Buechter et al., "Clinical trial of transdermal testosterone and oral levonorgestrel for male contraception," <i>The Journal of Clinical Endocrinology & Metabolism</i> , 84, No. 4, pp. 1244-1249 (1999)			
RB	AAO	English Abstract of WO96/03131 dated 08FEB96			
RB	AAP	World Health Organization, "Contraceptive efficacy of testosterone-induced azoospermia in normal men," <i>The Lancet</i> , 336, pp. 955-959 (1990)			
	AAQ				
Examiner Rachel M. Bennett				Date Considered 12/19/07	
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

English translation needed